• 1107 Citations
  • 19 h-Index
20052019
If you made any changes in Pure, your changes will be visible here soon.

Fingerprint Dive into the research topics where Tae-Yong Kim is active. These topic labels come from the works of this person. Together they form a unique fingerprint.

  • 44 Similar Profiles
Drug Therapy Medicine & Life Sciences
Breast Neoplasms Medicine & Life Sciences
Stomach Neoplasms Medicine & Life Sciences
Survival Medicine & Life Sciences
oxaliplatin Medicine & Life Sciences
Colorectal Neoplasms Medicine & Life Sciences
Disease-Free Survival Medicine & Life Sciences
Neoplasms Medicine & Life Sciences

Network Recent external collaboration on country level. Dive into details by clicking on the dots.

Research Output 2005 2019

  • 1107 Citations
  • 19 h-Index
  • 105 Article
  • 1 Conference contribution
1 Citation (Scopus)

Prognostic role of body mass index is different according to menopausal status and tumor subtype in breast cancer patients

Kim, J. Y., Lee, D. W., Lee, K-H., Min, A., Ryu, H. S., Lee, H-B., Moon, H. G., Kim, T-Y., Han, S-W., Oh, D-Y., Han, W., Park, I., Noh, D., Im, S-A. & Kim, S., 30 Jul 2019, In : Breast Cancer Research and Treatment. 176, 2, p. 453-460 8 p.

Research output: Contribution to journalArticleResearchpeer-review

Body Mass Index
Hormones
Breast Neoplasms
Thinness
Neoplasms

Quality of life outcomes including neuropathy-associated scale from a phase II, multicenter, randomized trial of eribulin plus gemcitabine versus paclitaxel plus gemcitabine as first-line chemotherapy for HER2-negative metastatic breast cancer: Korean Cancer Study Group Trial (KCSG BR13-11)

Kim, J. Y., Park, S., Im, S-A., Kim, S. B., Sohn, J., Lee, K. S., Chae, Y. S., Lee, K. H., Kim, J. H., Im, Y. H., Kim, T-Y., Lee, K-H., Ahn, J. H., Kim, G. M., Park, I. H., Lee, S. J., Han, H. S., Kim, S. H., Jung, K. H. & Park, Y. H., 28 May 2019, In : Cancer Communications. 39, 1, 29.

Research output: Contribution to journalArticleResearchpeer-review

Open Access
eribulin
gemcitabine
Paclitaxel
Multicenter Studies
Quality of Life

Prognostic effects of abnormal DNA damage response protein expression in breast cancer

Suh, K. J., Ryu, H. S., Lee, K-H., Kim, H., Min, A., Kim, T-Y., Yang, Y., Lee, H-B., Moon, H. G., Han, S-W., Oh, D-Y., Han, W., Park, I., Noh, D. & Im, S-A., 15 May 2019, In : Breast Cancer Research and Treatment. 175, 1, p. 117-127 11 p.

Research output: Contribution to journalArticleResearchpeer-review

DNA Damage
Breast Neoplasms
Proteins
Triple Negative Breast Neoplasms
Disease-Free Survival
1 Citation (Scopus)

A phase I/II study of poziotinib combined with paclitaxel and trastuzumab in patients with HER2-positive advanced gastric cancer

Kim, T-Y., Han, H. S., Lee, K-W., Zang, D. Y., Rha, S. Y., Park, Y. I., Kim, J. S., Lee, K-H., Park, S. H., Song, E. K., Jung, S. A., Lee, N. M., Kim, Y. H., Cho, J. Y. & Bang, Y. J., 1 Jan 2019, In : Gastric Cancer.

Research output: Contribution to journalArticleResearchpeer-review

Paclitaxel
Stomach Neoplasms
Maximum Tolerated Dose
HM781-36B
Trastuzumab
1 Citation (Scopus)

Pan-PIM kinase inhibitor AZD1208 suppresses tumor growth and synergistically interacts with AKT inhibition in gastric cancer cells

Lee, M., Lee, K-H., Min, A., Kim, J. E., Kim, S., Jang, H., Lim, J. M., Kim, S. H., Ha, D. H., Jeong, W. J., Suh, K. J., Yang, Y. W., Kim, T-Y., Oh, D-Y., Bang, Y. J. & Im, S-A., 1 Jan 2019, In : Cancer Research and Treatment. 51, 2, p. 451-463 13 p.

Research output: Contribution to journalArticleResearchpeer-review

Stomach Neoplasms
Phosphotransferases
Growth
Autophagy
Neoplasms